Thanks again to the authors and experts for making this forum happen. I'm thrilled to be able to take part! It’s always exciting when a study demonstrates an effect on primary endpoints, which is why IMPROVE-IT is so huge.
The question that lingers for me, however, is why are all-cause and cardiovascular mortality so difficult to modify using intensive vs. standard dose statins, and now other equivalent lipid lowering therapy, despite clear reductions in cardiovascular events? Is it something about the type of CV events that are prevented, i.e they’re more minor ones? Or is it an issue of power and the size of the potential study it would take to demonstrate out some of these effects?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.